What exclusive distribution rights has Uni-Bio Science Group secured from Chongqing Minji?

Question

Accepted Answer

Uni-Bio Science Group Secures Exclusive Nationwide Distribution Rights for Chongqing Minji's Wound Care and Skincare Devices

Uni-Bio Science Group Limited has secured exclusive nationwide distribution rights for two key medical devices from Chongqing Minji Medical Device Co., Ltd. These include a hydrogel wound dressing for post-injury and post-surgery healing and a collagen liquid dressing aimed at the medical aesthetics and daily skincare markets. These agreements mark a significant expansion for Uni-Bio Science Group into the medical device sector, complementing its existing biopharmaceutical offerings.
Exclusive Rights for Hydrogel Wound Dressing

The company has obtained the exclusive nationwide distribution rights for Chongqing Minji's hydrogel wound dressing. This product is specifically designed for the healing of wounds resulting from skin injuries and minimally invasive surgical procedures. It serves as a complementary offering to Uni-Bio Science Group's established GeneTime® (rEGF recombinant human epidermal growth factor) product, which is already utilized for burn and trauma treatment, thereby providing a more comprehensive solution from wound care to recovery.
Exclusive Rights for Collagen Liquid Dressing

Furthermore, Uni-Bio Science Group has secured exclusive distribution rights for Chongqing Minji's upcoming collagen liquid dressing. This class II medical device is positioned to cater to the premium segment of the medical aesthetics and daily skincare markets. Its introduction aligns with Uni-Bio Science Group's strategy to integrate its biopharmaceutical and medical device businesses with its cosmetic product lines, offering a complete skin care cycle from therapeutic treatment to aesthetic enhancement.
Strategic Expansion into Medical Aesthetics

These distribution agreements represent a strategic move by Uni-Bio Science Group to broaden its business scope into the medical aesthetics device sector. The company anticipates that the market size for medical device dressings and functional skincare products in China will reach significant figures by 2026, with projections indicating CNY 253.8 billion for medical device dressings and CNY 623 billion for functional skincare products. This partnership is expected to leverage the strengths of both companies in product registration, research and development, market channels, and brand influence.
Future Collaboration on Fibronectin-Based Devices

Beyond the immediate distribution rights, both Uni-Bio Science Group and Chongqing Minji will collaborate on developing novel medical device products. This joint effort will centre on Uni-Bio Science Group's proprietary core patented ingredient, Skbrella, a small molecular highly active recombinant human fibronectin. The objective is to develop and launch China's first class II medical devices utilising fibronectin, a component known for its significant skin repair and nourishment properties, thereby aiming to solidify leadership in the skincare and medical aesthetics fields.

Reading history

Hide →

This history is cleared when the page is closed.

What exclusive distribution rights has Uni-Bio Science Group secured from Chongqing Minji?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends